Positive new data on Goofice published in The Lancet

9 July 2018

Having seen its share leap around 20% on Friday following positive mid-stage results with an Alzheimer’s disease candidate, Japanese pharma major Eisai (TYO: 4523) rose 16.34% to 10,710 yen today after it announced new results have been published in the prestigious journal The Lancet on its gastrointestinal drug Goofice (elobixibat hydrate).

Results from two Phase III clinical trials (a 2-week double-blind placebo-controlled Phase III trial and an open-label single-arm 52-week long-term Phase III trial) for the bile acid transporter inhibitor Goofice have been published in The Lancet Gastroenterology & Hepatology.

Goofice, which is under development in with fellow Japan-based Mochida Pharmaceutical (TYO: 4534), was approved by the Japanese regulator in January this year and was launched on the domestic market in April.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK